α-Helical structure in the C-terminus of vasoactive intestinal peptide: Functional and structural consequences

European Journal of Pharmacology

Volumn 485, Issue 1-3, 2004, Pages 307-316

  Onoue, Satomi ^a,b   Matsumoto, Asami ^a   Nagano, Yumiko ^c   Ohshima, Keiichi ^d   Ohmori, Yuki ^e   Yamada, Shizuo ^e   Kimura, Ryohei ^e   Yajima, Takehiko ^b   Kashimoto, Kazuhisa ^a  

^a Itoham Foods Inc   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Binding activity; CD (Circular dichroism); Chemical synthesis; Helical structure; Relaxant activity; VIP (vasoactive intestinal peptide) derivative

Indexed keywords

AMINO ACID; METHIONINE; THREONINE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EVALUATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; STOMACH FUNCTION; SYNTHESIS;

EID: 1642497567     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.046     Document Type: Article

References (53)

1. Andrade M.A., Chacon P., Merelo J.J., Moran F. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng. 6:1993;383-390.
2. Blankenfeldt W., Nokihara K., Naruse S., Lessel U., Schomburg D., Wray V. NMR spectroscopic evidence that helodermin, unlike other members of the secretin/VIP family of peptides, is substantially structured in water. Biochemistry. 35:1996;5955-5962.
3. Bodanszky M., Bodanszky A. Conformation of peptides of the secretin-VIP-glucagon family in solution. Peptides. 7:1986;43-48.
4. Bodanszky M., Bodanszky A., Klausner Y.S., Said S.I. A preferred conformation in the vasoactive intestinal peptide (VIP). Molecular architecture of gastrointestinal hormones. Bioorg. Chem. 3:1974;133-140.
5. 1H nuclear magnetic resonance. J. Mol. Biol. 169:1983;921-948.
6. Brazeau P., Ling N., Bohlen P., Esch F., Ying S.Y., Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc. Natl. Acad. Sci. U. S. A. 79:1982;7909-7913.
7. Busto R., Carrero I., Guijarro L.G., Solano R.M., Zapatero J., Noguerales F., Prieto J.C. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung. Am. J. Physiol. 277:1999;L42-L48.
8. Chen Y.H., Yang J.T., Martinez H.M. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry. 11:1972;4120-4131.
9. Clore G.M., Martin S.R., Gronenborn A.M. Solution structure of human growth hormone releasing factor. Combined use of circular dichroism and nuclear magnetic resonance spectroscopy. J. Mol. Biol. 191:1986;553-561.
10. Delgado M., Munoz-Elias E.J., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J. Immunol. 162:1999;4685-4696.
11. Fournier A., Saunders J.K., Boulanger Y., St-Pierre S. Conformational analysis of vasoactive intestinal peptide and related fragments. Ann. N.Y. Acad. Sci. 527:1988;51-67.
12. Gourlet P., Vilardaga J.P., De Neef P., Waelbroeck M., Vandermeers A., Robberecht P. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides. 17:1996;825-829.
13. Greenfield N., Fasman G.D. Computed circular dichroism spectra for the evaluation of protein conformation. Biochemistry. 8:1969;4108-4116.
14. 1H-NMR study of the solution conformation of secretin. Resonance assignment and secondary structure. FEBS Lett. 215:1987;88-94.
15. 2, a fragment with analgesic properties. Pept. Res. 9:1996;327-331.
16. Hoshino M., Yanaihara C., Hong Y.M., Kishida S., Katsumaru Y., Vandermeers A., Vandermeers-Piret M.C., Robberecht P., Christophe J., Yanaihara N. Primary structure of helodermin, a VIP-secretin-like peptide isolated from Gila monster venom. FEBS Lett. 178:1984;233-239.
17. Inagaki N., Kuromi H., Seino S. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Ann. N.Y. Acad. Sci. 805:1996;44-51.
18. Jorpes J.E. The isolation and chemistry of secretin and cholecystokinin. Gastroenterology. 55:1968;157-164.
19. Kitada C., Sakiyama A., Watanabe T., Fujino M. Synthesis and structure-activity relationships of PACAP. Pept. Chem. 1990:1991;239-244.
20. Kobayashi S., Takeshima K., Park C.B., Kim S.C., Matsuzaki K. Interactions of the novel antimicrobial peptide buforin 2 with lipid bilayers: proline as a translocation promoting factor. Biochemistry. 39:2000;8648-8654.
21. Leroux P., Vaudry H., Fournier A., St-Pierre S., Pelletier G. Characterization and localization of vasoactive intestinal peptide receptors in the rat lung. Endocrinology. 114:1984;1506-1512.
22. Li M., Hoshino M., Zheng L., Naruse S., Yanaihara C., Ohshima K., Iguchi K., Mochizuki T., Yanaihara N. Helodermin analogues: structure-function studies of helodermin. Biomed. Res. 14:1993;61-69.
23. Liu X., Garriga P., Khorana H.G. Structure and function in rhodopsin: correct folding and misfolding in two point mutants in the intradiscal domain of rhodopsin identified in retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 93:1996;4554-4559.
24. Merrifield R.B. Solid-phase peptide synthesis. Advan. Enzymol. Relat. Areas Mol. Biol. 32:1969;221-296.
25. Minn I., Kim H.S., Kim S.C. Antimicrobial peptides derived from pepsinogens in the stomach of the bullfrog, Rana catesbeiana. Biochim. Biophys. Acta. 1407:1998;31-39.
26. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164:1989;567-574.
27. Miyata A., Jiang L., Dahl R.D., Kitada C., Kubo K., Fujino M., Minamino N., Arimura A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 170:1990;643-648.
28. O'Donnell M., Garippa R.J., Rinaldi N., Selig W.M., Tocker J.E., Tannu S.A., Wasserman M.A., Welton A., Bolin D.R. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. J. Pharmacol. Exp. Ther. 270:1994;1289-1294.
29. Onoue S., Nagano Y., Tatsuno I., Uchida D., Kashimoto K. Receptor-binding specificity depending on N-terminal structure of VIP/PACAP. Biomed. Res. 20:1999;219-231.
30. Onoue S., Waki Y., Nagano Y., Satoh S., Kashimoto K. The neuromodulatory effects of VIP/PACAP on PC-12 cells are associated with their N-terminal structures. Peptides. 22:2001;867-872.
31. Onoue S., Nagano Y., Endo K., Yajima T., Kashimoto K. Differences in biological activity between PACAP27 and VIP in PC12 cells depend on their N-terminal structure. Pharmacol. Rev. Commun. 12:2002;205-213.
32. Park I.Y., Park C.B., Kim M.S., Kim S.C. Parasin I, an antimicrobial peptide derived from histone H2A in the catfish, Parasilurus asotus. FEBS Lett. 437:1998;258-262.
33. Park C.B., Yi K.S., Matsuzaki K., Kim M.S., Kim S.C. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8245-8250.
34. Parkman H.P., Pagano A.P., Ryan J.P. PACAP and VIP inhibit pyloric muscle through VIP/PACAP-preferring receptors. Regul. Pept. 71:1997;185-190.
35. Rawlings S.R., Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr. Rev. 17:1996;4-29.
36. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60:2000;3105-3112.
37. Rivier J., Spiess J., Thorner M., Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 300:1982;276-278.
38. Robberecht P., De Neef P., Lefebvre R.A. Influence of selective VIP receptor agonists in the rat gastric fundus. Eur. J. Pharmacol. 359:1998;77-80.
39. Robinson R.M., Blakeney E.W. Jr., Mattice W.L. Lipid-induced conformational changes in glucagon, secretin, and vasoactive intestinal peptide. Biopolymers. 21:1982;1228-1271.
40. Said S.I. Vasoactive intestinal polypeptide and asthma. N. Engl. J. Med. 320:1989;1271-1273.
41. Said S.I. Vasoactive intestinal polypeptide (VIP) in asthma. Ann. N.Y. Acad. Sci. 629:1991;305-318.
42. Said S.I., Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science. 169:1970;1217-1218.
43. Sreerama N., Woody R.W. Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal. Biochem. 287:2000;252-260.
44. Sun L., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J. Neuroimmunol. 48:1993;59-69.
45. Tanaka T., Miwa N., Kawamura S., Sohma H., Nitta K., Matsushima N. Molecular modeling of single polypeptide chain of calcium-binding protein p26olf from dimeric S100B(betabeta). Protein Eng. 12:1999;395-405.
46. Theriault Y., Boulanger Y., St-Pierre S. Structural determination of the vasoactive intestinal peptide by two-dimensional H-NMR spectroscopy. Biopolymers. 31:1991;459-464.
47. Turner J.T., Jones S.B., Bylund D.B. A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29. Peptides. 7:1986;849-854.
48. Unger R.H., Dobbs R.E., Orci L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu. Rev. Physiol. 40:1978;307-343.
49. Vandermeers A., Vandenborre S., Hou X., de Neef P., Robberecht P., Vandermeers-Piret M.C., Christophe J. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes. Eur. J. Biochem. 208:1992;815-819.
50. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52:2000;269-324.
51. Wray V., Kakoschke C., Nokihara K., Naruse S. Solution structure of pituitary adenylate cyclase activating polypeptide by nuclear magnetic resonance spectroscopy. Biochemistry. 32:1993;5832-5841.
52. Wray V., Nokihara K., Naruse S. Solution structure comparison of the VIP/PACAP family of peptides by NMR spectroscopy. Ann. N.Y. Acad. Sci. 865:1998;37-44.
53. Yoshihara S., Linden A., Kashimoto K., Watanabe S. A novel long-acting VIP analog in the guinea pig trachea in vitro. Peptides. 19:1998;593-597.